Disclosure Of First-Time Adoption [Text Block]

Ascelia Pharma - Filing #678716

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	74 328 SEK	—	639 962 SEK	—	—	- SEK	—	—	34 871 SEK	671,000 SEK	74 328 SEK	—	678 747 SEK	180 859 SEK	—	—	—	—	- SEK	533 732 SEK	34 871 SEK	972,000 SEK	180 859 SEK	678 747 SEK	—	—	—	405 827 SEK	678 831 SEK	307 834 SEK	307 834 SEK	- SEK	254,000 SEK	34 576 SEK
Comprehensive income	109 589 SEK	—	109 589 SEK	—	- SEK	109 288 SEK	—	301,000 SEK	- SEK	—	—	—	- SEK	—	—	- SEK	130 504 SEK	131 223 SEK	- SEK	—	—	—	—	—	—	130 504 SEK	718,000 SEK	- SEK	—	—	—	—	—	—	—
Profit (loss)	109 288 SEK	—	109 288 SEK	—	- SEK	109 288 SEK	—	- SEK	- SEK	—	—	—	- SEK	—	—	- SEK	131 223 SEK	131 223 SEK	- SEK	—	—	—	—	—	—	131 223 SEK	- SEK	- SEK	—	—	—	—	—	—	—